Mitral valve surgery (including mitral valvuloplasty and replacement) is one of the more frequently performed minimally invasive robotic procedures. It has good surgical results and a high mitral valvuloplasty rate. Postoperative anticoagulation therapy is the same as conventional open-heart principles. The current standard is to maintain an INR (International Normalized Ratio) of about 1.8 to 2.2 after mitral mechanical valve replacement; the biological valve is controlled at about 2.0. If there is no atrial fibrillation or atrial thrombus after bioprosthetic valve replacement, stopping anticoagulation after 1 year or 6 months can be considered, depending on the specific situation. The incision is essentially the same as the robotic cardiac surgery incision, and considerations can be found in the previous article. Tricuspid valve lesions can be treated concurrently with mitral valve surgery, and concurrent tricuspid valvuloplasty can be considered in patients with preoperative combined mitral valve insufficiency of moderate to severe severity.